The evaluation of patients with optic disc edema: A retrospective study

Selma Urfalioglu, Gokhan Ozdemir, Mete Guler, Gamze Gizem Duman
Department of Ophthalmology, Kahramanmaras Sutcu Imam University Faculty of Medicine, Kahramanmaras, Turkey

ABSTRACT

OBJECTIVE: Optic disc edema is among major problems that neuro-ophthalmology clinics encounter. We intended to analyze patients with optic disc edema in this article.

METHODS: Data related to the main complaint, associated systemic disease, visual acuity, characteristics of optic disc swelling, other ocular findings, topical or systemic drugs, treatment methods, follow-up examination, and related data of the patients were obtained retrospectively.

RESULTS: There were 77 female and 23 male patients in the study. Optic disc edema was detected bilaterally in 65 patients, unilaterally in 35 patients. The duration of the symptoms until the first application was 19.82±17.18 (0–90) days. There were no systemic disorders in 74 patients but diabetes mellitus in 11 patients, hypertension in four patients, coronary artery disease in three patients, urticaria in two patients, lymphoma in one, multiple sclerosis in one patient, mastoiditis in one patient, scleroderma in one, and pregnancy in two patients were detected. While 93 patients had no additional ocular findings, 2 had uveitis, 1 had corneal dystrophy, 1 had keratoconus, 1 had cataract, 1 had previous cataract surgery, and 1 had peripheral retinal degenerations. The major etiology of the optic disc edema was idiopathic intracranial hypertension, which was detected in 44 patients. In all these patients, bilateral optic disc edema was observed and 43 patients were given oral acetazolamide and one patient oral topiramate.

CONCLUSION: The presence of optic nerve edema should be absolutely evaluated in patients presenting with symptoms of vision loss and increased intracranial pressure. The early diagnosis with fundoscopic examination may increase visual acuity in these patients.

Keywords: Etiology; ocular findings; optic disc edema.

Cite this article as: Urfalioglu S, Ozdemir G, Guler M, Duman GG. The evaluation of patients with optic disc edema: A retrospective study. North Clin Istanb 2021;8(3):280–285.

Optic disc edema is swelling of intraocular portion of the optic nerve. The axons of retinal ganglion cell which forms the nerve exit the eye through scleral lamina cribrosa and convey the visual signal to the occipital cortex. The compression of the fibers in the lamina cribrosa leads to tissue edema and increases intercellular matrix pressure [1]. Optic disc edema may present with optic nerve head bulging, hyperemia, loss of optic disc boundaries, vascular congestion and peripapillary hemorrhages [2]. A binocular indirect fundoscopy is essential to document optic disc findings. Especially, central venous pulsation loss is an important finding in the examination. Although the disc edema is isolated generally, sometimes retinal edema may accompany the picture and may give rise to nevoretinitis.

These patients may demonstrate symptoms of visual loss, headache, nausea, vomiting, pain on ocular motility, decreased color vision, constriction of visu-
al field, and diplopia. The visual loss may range from mild to profound degree and an important cause for patient morbidity.

Optic disc edema arises from the blockage of retrograde and orthograde axoplasmic transport in the optic nerve [3]. Inflammatory, infectious, and other factors may impede the flow and various factors should be considered in evaluation of such patients including age, systemic disorders, duration of symptoms, visual loss, and unilaterality or bilaterality of the disease. Optic disc edema is among major problems that neuro-ophthalmology clinics encounter. Therefore, although not very valid in common practice, a comprehensive examination accompanying the diagnosis should be performed and patients should be searched ophthalmologically and systematically. In this article, we intended to analyze patients with optic disc edema.

**MATERIALS AND METHODS**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was conducted after getting the approval of the Kahramanmaras Sutcu Imam University Clinical Research Ethics Committee (approval number-date: 452-07.11.2018) and the patients who had the diagnosis of optic disc edema between January 2014 and November 2018 were determined from hospital electronic database retrospectively.

The data regarding the basic complaint, onset of symptoms, associated systemic disease, visual acuity, characteristics of optic disc swelling, other ocular findings, topical or systemic medications, radiological investigations including magnetic resonance imaging (MRI) and computerized tomography, treatment modalities, follow-up examination, and related data were obtained from the files of the patients.

In all patients, full ophthalmological examination including dilated fundus examination and visual acuity on a standard Snellen visual acuity chart had been earlier performed. Neuroradiological and other related consultations had been done and the final diagnosis of the patients had been ensured according to these results. The management of the patient according to the presumed diagnosis was recorded as well.

**Highlight key points**

- Optic disc edema may develop due to many ocular and systemic diseases.
- In patients with optic disc edema, detailed clinical and radiological examinations should be performed to determine the underlying cause.
- Treatment based on the cause can help prevent vision loss in these patients.

**Statistical Analysis**

The comparison of the data was done with a statistical software program (SPSS 20, IBM, Chicago, ILL). Numerical variables were given as mean±standard deviation, frequency, and percentage, and Wilcoxon signed-rank test was used for comparison of the means.

**RESULTS**

A total of 100 patients were included into the study finally after excluding patients with missing data and incomplete follow-up. The mean age of the patients was 38.58±15.11 (12–76) years. There were 77 (77%) female and 23 (23%) male patients in the study.

Sixtythree patients presented due to visual loss, 33 headaches, two with diplopia, two with headache, and one with photophobia. One patient was diagnosed with optic disc edema on a regular examination without any complaint.

Optic disc edema was detected bilaterally in 65 patients, unilaterally in 35 patients. The duration of the symptoms until the first application was 19.82±17.18 (0–90) days. There were no systemic disorders in 74 patients but diabetes mellitus in 11 patients, hypertension in four patients, coronary artery disease in three patients, urticaria in two patients, lymphoma in one, multiple sclerosis in one patient, mastoiditis in one patient, scleroderma in one, and pregnancy in two patients were detected. While 93 patients had no additional ocular findings, 2 had uveitis, 1 had corneal dystrophy, 1 had keratoconus, 1 had cataract, 1 had previous cataract surgery, and 1 had peripheral retinal degenerations.

While the medication history revealed that 82% of the patients used no medication, 10% of the patients used antidiabetics, 4% of the patients antihypertensives, 3% immunosuppressives, and 1% antibiotics.

In 13 of 65 patients with bilaterally edema and 13 of 35 patients with unilaterally edema had concomitant sys-
Neuroradiological investigations demonstrated that no findings in 79 patients, while 21 patients showed pathological manifestations. As radiologically, ischemic optic neuropathy in 5 patients, optic neuritis in 4 patients, signs of idiopathic intracranial hypertension (IIH) in 4 patients, optic disc drusen in 3 patients, cavernous sinus thrombosis in 2 patients, intracranial mass in 2 patients, and diabetic papillopathy in 1 patient were detected.

Based on these evaluations, the diagnosis of patients were as follows: 44 patients IIH, 22 patients optic neuritis, seven patients non-arteritic ischemic optic neuropathy, three patients optic disc drusen, three patients hypertensive papillopathy, two patients cavernous sinus thrombosis, two patients diabetic papillopathy, two patients retinal vein occlusions, two patients intracranial mass, one patients Harada syndrome, and one patient sarcoidosis. Investigations yielded no possible diagnosis in 11 patients.

The IIH was the most common etiology causing optic disc edema in our study. In the study, there were 44 IIH patients, of which 42 were female and two were male. Optic disc edema due to IIH is specifically called papilledema, though these two terms may be mistakenly used interchangeably sometimes [2]. IIHs are presumed to be generated due to decreased absorption of cerebrospinal fluid (CSF) through arachnoid villi [5]. Having an annual incidence of 0.9 in 100,000 people, it affects frequently obese fertile women aged between 20 and 44 years [6]. Obesity may increase CSF pressure by increased intra-abdominal pressure pressing on medulla spinalis or decreases.
ing venous return to the heart from the brain [7]. Patients generally apply to physician due to headache, blurred vision, photophobia, tinnitus, or diplopia although asymptomatic cases have also been reported [8, 9]. Diagnosis can be achieved with a high CSF pressure, radiological methods, and normal CSF biochemistry in addition to the presence of a optic disc edema [10]. Treatment relies on decreasing the production of CSF by acetazolamide, topiramate, furosemide, or in some cases minimal corticosteroids [11, 12]. Furthermore, there are some researches reporting that weight loss could help improve the prognosis [13]. Our study is in congruity with the literature that IIHs were seen mostly in young female patients who responded well to acetazolamide therapy. Eating habits and nutritional preferences depending on the geographical area are seen major factors causing expansion of obesity in our country and worldwide. In our study, IIH may be related to high obesity frequency encountered in this region.

In our study, 22 patients were diagnosed as optic neuritis, which was the second most common cause of optic nerve head edema. It is non-infectious inflammation of the optic nerve and can be classified as papillitis, retrobulbar neuritis, or typical/atypical optic neuritis. Typical optic neuritis is generally associated with multiple sclerosis, which is acute, inflammatory demyelinating disease with relatively milder prognosis. Atypical optic neuritis is a kind of optic neuritis developed due to infectious, inflammatory reasons other than multiple sclerosis or autoimmune causes [14, 15]. The optic neuritis has an incidence of 1–2/100,000 people and is generally common among young, white, female population [14].

Unilateral central acute visual loss is a commonly encountered symptom and relative afferent pupillary defect and color vision disturbance generally accompany the disease at early period. MRI and CSF analyses should be undertaken essentially to rule out multiple sclerosis (MS) in isolated optic neuritis cases [16, 17].

Optic neuritis treatment trial demonstrated that a patient with a diagnosis of optic neuritis had a risk of MS development of 40% in 10 years. For optic neuritis patients with normal MRI, this risk is 22% while patients having 3 mm plaques on MRI have a risk of 56% [16, 18].

### Table 2. Age, sex, laterality, and the number of patients treated according to diagnoses and visual acuities at initial application and at the end of the follow-up

| Diagnosis                                      | Unilateral | Bilateral | Age          | Male | Female | Initial visual acuity | Last visual acuity | Treatment |
|------------------------------------------------|------------|-----------|--------------|------|--------|-----------------------|--------------------|-----------|
| Idiopathic intracranial hypertension           | 0          | 44        | 33.38±10.50  | 2    | 42     | 0.85±0.30 (0.1–1.0)    | 0.92±1.82 (0.1–1.0) | 44        |
| Optic neuritis                                 | 17         | 5         | 40.30±16.69  | 10   | 12     | 0.47±0.24 (0.1–1.0)    | 0.62±0.33 (0.1–1.0) | 22        |
| Non-arteritic ischemic optic neuropathy        | 7          | 0         | 64.86±9.23   | 4    | 3      | 0.41±0.28 (0.1–1.0)    | 0.43±0.31 (0.1–1.0) | 7         |
| Optic disc drusen                              | 1          | 2         | 27.33±11.01  | 0    | 3      | 1.0                   | 1.0                | –         |
| Hypertensive papillopathy                      | 0          | 3         | 42.00±5.66   | 2    | 1      | 0.80±0.28 (0.6–1.0)    | 0.80±0.28 (0.6–1.0) | 3         |
| Diabetic papillopathy                          | 0          | 2         | 46.50±17.67  | 0    | 2      | 0.80±0.14 (0.7–0.9)    | 0.80±0.14 (0.7–0.9) | 1         |
| Cavernous sinus thrombosis                     | 0          | 2         | 35.00±5.66   | 0    | 2      | 1.0                   | 1.0                | 2         |
| Retinal vein occlusions                        | 2          | 0         | 59.5±9.19    | 0    | 2      | 0.30±0.28 (0.1–0.5)    | 0.60±0.00 (0.6–0.6) | 2         |
| Intracranial mass                              | 1          | 1         | 46.50±2.12   | 1    | 1      | 1.0                   | 1.0                | 2         |
| Harada syndrome                                | 0          | 1         | 19           | 0    | 1      | 0.9                   | 1.0                | 1         |
| Sarcoidosis                                    | 1          | 0         | 31           | 1    | 0      | 0.7                   | 1.0                | 1         |
| No diagnosis                                   | 6          | 5         | 37.91±15.60  | 3    | 8      | 0.61±0.36 (0.1–1.0)    | 0.53±0.36 (0.1–1.0) | 4         |
| Total                                          | 35         | 65        |              | 25   | 75     |                       |                    | 89        |
Therapeutic corticosteroids may improve visual prognosis in early period but have no effect at the end of 3 years. Immunomodulatory interferons could be suggested since they reduce relapse frequency [18]. In atypical optic neuritis, therapy should be oriented toward etiology and steroids along with other immunosuppressive drugs may improve prognosis substantially in neuromyelitis optica [14, 18]. In our study, investigation to reveal the underlying etiology of the cases was carried out but still many cases remained undiagnosed and only one optic neuritis case who had been diagnosed with MS before was detected.

Non-arteritic ischemic optic neuropathy is another possible cause of optic disc edema, which is characterized with painless acute visual loss in patients over 50 years of age [19] and was detected in seven patients in our study. It has a reported incidence of 2–10 in 100,000 people and does not show any gender tendency [20]. Diabetes mellitus, hypertension, smoking, acute hemorrhage, anemia, and hypotension are among the risk factors reported [21]. There is not any certain treatment modality for the disease but anticoagulants, subcutaneous vasodilators, and thrombolytics have been tried with limited success [22]. The role of corticosteroids is controversial and not free from side effects, especially in diabetic hypertensive, and elderly people, in spite of some probable positive effects, its use is limited [23]. ASA has no role in the treatment of non-arteritic ischemic optic neuropathy but its use may have a protective effect on the fellow eye [24]. Our study found similar clinical features with the literature with regard to this patient group.

Uncontrolled diabetes and hypertension may lead to diabetic papillopathy bilaterally or unilaterally and we had two patients with this clinical entity [25, 26]. The disc edema in diabetic papillopathy is caused by microvascular circulation disorder of the optic disc, and pronounced telangiectatic vessels may be difficult to distinguish from neovascularization. The moderate vision loss may occur in these. Diabetic papillopathy can occur in the settings with no diabetic retinopathy. The treatment of associated systemic disorders may help alleviate disc edema. Systemic steroid should be avoided not to worsen blood sugar and hypertension control but the use of intravitreal triamcinolone was reported in some research [27, 28]. In our study, it was found that these patients with uncontrolled diabetes and hypertension were treated with endocrinology and nephrology clinics through consultation.

Pseudopapilledema is swollen appearance of optic disc in conditions without any disease. This condition should be distinguished before any treatment is supplemented. Optic disc drusen, myelinated nerve fibers, and high hypermetropia may give rise to a pseudopapilledema appearance. Optic disc drusen could be differentiated easily with autofluorescence, ultrasonography, computerized tomography, and optic coherence tomography [29, 30]. These drusen materials are calcified hyaline bodies and do not require any treatment.

Posterior uveitis, retinal vein occlusion, posterior scleritis, and other systemic infections (tuberculosis, lepra, etc.) and autoimmune disorders (Harada disease, sarcoidosis, etc.) can lead to optic disc edema [1]. The treatment should be tailored according to the etiology in these cases.

There are some limitations in our study. First, there were some patients who did not have enough data in their files, which required the exclusion of those patients. Furthermore, despite clinical and radiological research, no reason for optical disc edema was found in some. There could be other patients whom we were unable to detect and missed due to some mistakes at diagnosis entry since we searched our database for predetermined diagnostic terms such as optic neuritis or optic disc edema.

Conclusion

Optic disc edema is a manifestation of several disorders rather than a diagnosis and should be detected at an early level. A thorough clinical investigation should aid the physician to make decisions and a detailed approach should accompany the management. The presence of optic nerve edema should be absolutely evaluated in patients presenting with symptoms of vision loss and increased intracranial pressure. As well as early diagnosis with fundoscopic examination before neuroradiological examinations, a treatment can be arranged that according to etiological factors may increase visual acuity in these patients.

Ethics Committee Approval: The Kahramanmaras Sutcu Imam University Clinical Research Ethics Committee granted approval for this study (date: 07.11.2018, number: 452).

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – SU, MG, GO; Design – SU, MG, GGD; Materials – SU, GO, GGD; Data collection and/or processing – SU, MG, GO, GGD; Analysis and/or interpretation – SU, GO, GGD; Writing – SU, MG; Critical review – MG, GO.
REFERENCES

1. Selhorst JB, Chen Y. The optic nerve. Semin Neurol. 2009 Feb;29(1):29-35.
2. Ehlers JP, Shah CP, Fenton GL, Hoskins EN, Shelsta HN. Papilledema. In: The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2008. p. 252-4.
3. Schirmer CM, Hedges TR 3rd. Mechanisms of visual loss in papilledema. Neurosurg Focus 2007;23:E5.
4. Van Stavern GP. Optic disc edema. Semin Neurol 2007;27:233-43.
5. Owler BK, Parker G, Halmagyi GM, Johnston IH, Besser M, Pickard JD, et al. Cranial venous outflow obstruction and pseudotumor Cerebri syndrome. Adv Tech Stand Neurosurg 2005;30:107-74.
6. Friedman DI. The pseudotumor cerebri syndrome. Neuror Clin 2014;32:363-96.
7. Orefice G, Celentano L, Scaglione M, Davoli M, Striano S. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli) 1992;14:39-50.
8. Huna-Baron R, Landau K, Rosenberg M, Warren FA, Kupersmith MJ. Unilateral swollen disc due to increased intracranial pressure. Neurology 2001;56:1588—90.
9. Friedman DI. Idiopathic intracranial hypertension. Curr Pain Headache Rep 2007;11:62-8.
10. Wall M. Idiopathic intracranial hypertension. Neuror Clin 2010;28:593—617.
11. Roberts PA, Pollay M, Engles C, Pendleton B, Reynolds E, Stevens FA. Effect on intracranial pressure of furosemide combined with varying doses and administration rates of mannitol. J Neurosurg 1987;66:440—6.
12. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998;105:2313—7.
13. Wong R, Madill SA, Pandey P, Riordan-Eva P. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol 2007;7:15.
14. Jenkins TM, Toosy AT. Optic neuritis: the eye as a window to the brain. Curr Opin Neurol 2017;30:61-6.
15. Jenkins TM, Toosy AT. New developments in the treatment of optic neuritis. Eye Brain 2010;2:83—94.
16. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008;65:727—32.
17. Agostoni E, Frigerio R, Protti A. Controversies in optic neuritis pain diagnosis. Neurol Sci 2005;26 Suppl 2:s75—8.
18. Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al; Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003;121:944—9.
19. Atkins EJ. Nonarteritic anterior ischemic optic neuropathy. Curr Treat Options Neurol 2011;13:92—100.
20. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997;123:103—7.
21. Xiao YY, Wei WB, Wang YX, Lu AD, Chen SH, Song L, et al. Systemic-related factors of nonarteritic anterior ischemic optic neuropathy. Chin Med J (Engl) 2018;131:2357—9.
22. Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 2010;55:47—63.
23. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008;246:1029—46.
24. Beck RW, Hayreh SS. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) 2000;14:118.
25. Mitra A. Bilateral papillophlebitis in a patient with accelerated essential hypertension. Ann Ophthalmal (Skokie) 2007;39:337—9.
26. Appen RE, Chandra SR, Klein R, Myers FL. Diabetic papillopathy. Am J Ophthalmol 1980;90:203—9.
27. Slagle WS, Musick AN, Eckermann DR. Diabetic papillopathy and its relation to optic nerve ischemia. Optom Vis Sci 2009;86:e395—403.
28. Al-Haddad CE, Jurdì FA, Bashshur ZF. Intravitreal triamcinolone acetate for the management of diabetic papillopathy. Am J Ophthalmol 2004;137:1151—3.
29. Gutteridge IF. Optic nerve drusen and pseudopapilledema. Am J Optom Physiol Oph 1981;58:671—6.
30. Bassi ST, Mohana KP. Optical coherence tomography in papilledema and pseudopapilledema with and without optic nerve head drusen. Indian J Ophthalmol 2014;62:1146—51.